person · Reporting owner

Thompson Elizabeth H.Z.

Disclosed activity across 3 companies

Tapewire entity: 27578
SEC CIK: 0001861477

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACADIA PHARMACEUTICALS INCACAD · Entity 3913	EVP, Head of Research & Dev	July 29, 2026	July 31, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACADIA PHARMACEUTICALS INC

Report date July 29, 2026 · Filed July 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,994	Ending reported balance After 2026-07-30 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-07-29 · Exercise / conversion · Acquired 32,272 · Balance 35,552 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-07-30 · Sale · Disposed 16,508 · Balance 19,044 F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Row 3 · 2026-07-30 · Sale · Disposed 50 · Balance 18,994 F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	32,272	Reported balance After 2026-07-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-29 · Exercise / conversion · Disposed 32,272 · Balance 32,272 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: 50% of the restricted stock units vested on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F2: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

F3: 50% of the restricted stock units vested on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Horizon Therapeutics Public Ltd Co

Report date October 06, 2023 · Filed October 06, 2023

Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-10-06 transaction · row 1 1 source row Row 1 · 2023-10-06 · Disposition to issuer · Disposed 14,575 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-10-06 · Disposition to issuer · Disposed 4,657 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F3: The Ordinary Shares subject to the RSUs (as defined in footnote 4 to this Form 4") vest on January 5, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-06 · Disposition to issuer · Disposed 14,283 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F5: The Ordinary Shares subject to the RSUs vest ratably on January 5, 2024 and January 5, 2025.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-10-06 · Disposition to issuer · Disposed 20,697 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F6: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-10-06 · Disposition to issuer · Disposed 4,285 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F7: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4") vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-10-06 · Disposition to issuer · Disposed 12,854 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F9: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-10-06 · Disposition to issuer · Disposed 21,426 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F9: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-10-06 · Disposition to issuer · Disposed 10,349 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F10: The Ordinary Shares subject to the PSUs vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-10-06 · Disposition to issuer · Disposed 5,174 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-10-06 · Disposition to issuer · Disposed 5,174 · Balance 0 F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").

F2: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.

F3: The Ordinary Shares subject to the RSUs (as defined in footnote 4 to this Form 4") vest on January 5, 2024.

F4: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.

F5: The Ordinary Shares subject to the RSUs vest ratably on January 5, 2024 and January 5, 2025.

F6: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.

F7: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4") vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.

F8: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.

F9: The Ordinary Shares subject to the PSUs vest on January 5, 2025.

F10: The Ordinary Shares subject to the PSUs vest on January 5, 2026.

F11: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.

IGM Biosciences, Inc.

Report date August 14, 2025 · Filed August 14, 2025

Section 16 reporting ended · disclosed 2025-08-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-08-14 transaction · row 1 1 source row Row 1 · 2025-08-14 · Disposition to issuer · Disposed 7,196 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 30, 2026 Filed Jul 31, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	50	$26.17	$1,308.50	Disclosure SEC source: 0001861477-26-000005 · form4-07312026_060701.xml · nonDerivative · entry 3 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,994 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
July 30, 2026 Filed Jul 31, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	16,508	$26.13	$431,354.04	Disclosure SEC source: 0001861477-26-000005 · form4-07312026_060701.xml · nonDerivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,044 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
July 29, 2026 Filed Jul 31, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	32,272	$0.00	$0.00	Disclosure SEC source: 0001861477-26-000005 · form4-07312026_060701.xml · derivative · entry 4 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,272 Underlying: Common Stock · 32,272 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the restricted stock units vested on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028. F3 · derivative.expiration_date: 50% of the restricted stock units vested on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028. Read SEC document
July 29, 2026 Filed Jul 31, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	32,272	Not disclosed	Not disclosed	Disclosure SEC source: 0001861477-26-000005 · form4-07312026_060701.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 25, 2026 Filed Mar 27, 2026 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	SaleCommon Stock	3,435	$21.47	$73,749.45	Disclosure SEC source: 0001861477-26-000003 · form4-03262026_080306.xml · nonDerivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,280 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
March 24, 2026 Filed Mar 27, 2026 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionRestricted Stock Units · Derivative	6,715	$0.00	$0.00	Disclosure SEC source: 0001861477-26-000003 · form4-03262026_080306.xml · derivative · entry 3 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,146 Underlying: Common Stock · 6,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. Read SEC document
March 24, 2026 Filed Mar 27, 2026 00:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	Exercise / conversionCommon Stock	6,715	Not disclosed	Not disclosed	Disclosure SEC source: 0001861477-26-000003 · form4-03262026_080306.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
March 06, 2026 Filed Mar 10, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	29,548	$0.00	$0.00	Disclosure SEC source: 0001861477-26-000002 · form4-03102026_060307.xml · derivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,548 Underlying: Common Stock · 29,548 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 6, 2027. Read SEC document
March 06, 2026 Filed Mar 10, 2026 22:00 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Option (Right to Buy) · Derivative	101,574	$0.00 Strike: $22.16	$0.00	Disclosure SEC source: 0001861477-26-000002 · form4-03102026_060307.xml · derivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,574 Underlying: Common Stock · 101,574 shares Expires 2036-03-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
August 14, 2025 Filed Aug 14, 2025 21:25 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	Disposition to issuerCommon Stock	7,196	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-021961 · form4-08142025_090827.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. F1 · price: Pursuant to the Agreement and Plan of Merger dated July 1, 2025, by and among IGM Biosciences, Inc. (the "Company"), Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), on August 14, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive (i) an amount equal to $1.247 in cash and (ii) one contractual contingent value right (a "CVR") subject to the terms and conditions of a Contingent Value Rights Agreement. Read SEC document
June 30, 2025 Filed Jul 2, 2025 22:52 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantCommon Stock	694	$0.00	$0.00	Disclosure SEC source: 0001415889-25-019153 · form4-07022025_100728.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,196 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects partial payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document
March 31, 2025 Filed Apr 2, 2025 23:01 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantCommon Stock	694	$0.00	$0.00	Disclosure SEC source: 0001415889-25-009778 · form4-04022025_110456.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,502 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects partial payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document
March 24, 2025 Filed Mar 26, 2025 23:52 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	26,861	$0.00	$0.00	Disclosure SEC source: 0001415889-25-009068 · form4-03262025_110352.xml · derivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,861 Underlying: Common Stock · 26,861 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning March 24, 2026. Read SEC document
March 24, 2025 Filed Mar 26, 2025 23:52 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Option (Right to Buy) · Derivative	91,395	$0.00 Strike: $17.23	$0.00	Disclosure SEC source: 0001415889-25-009068 · form4-03262025_110352.xml · derivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,395 Underlying: Common Stock · 91,395 shares Expires 2035-03-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
December 31, 2024 Filed Jan 3, 2025 22:55 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantCommon Stock	1,452	$0.00	$0.00	Disclosure SEC source: 0001415889-25-000609 · form4-01032025_100126.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,808 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects partial payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document
September 30, 2024 Filed Oct 2, 2024 23:59 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantCommon Stock	1,452	$0.00	$0.00	Disclosure SEC source: 0001415889-24-024534 · form4-10022024_111059.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,356 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects partial payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document
August 12, 2024 Filed Aug 13, 2024 22:05 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantRestricted Stock Units · Derivative	64,544	$0.00	$0.00	Disclosure SEC source: 0001415889-24-021243 · form4-08132024_060801.xml · derivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,544 Underlying: Common Stock · 64,544 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F3 · derivative.exercise_date: 50% of the restricted stock units vest on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028. F3 · derivative.expiration_date: 50% of the restricted stock units vest on July 29, 2026 and 25% vest on each of July 29, 2027 and July 29, 2028. Read SEC document
August 12, 2024 Filed Aug 13, 2024 22:05 UTC	ACADIA PHARMACEUTICALS INC ACAD · Entity 3913	GrantStock Option (Right to Buy) · Derivative	324,582	$0.00 Strike: $15.29	$0.00	Disclosure SEC source: 0001415889-24-021243 · form4-08132024_060801.xml · derivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Head of Research & Dev 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,582 Underlying: Common Stock · 324,582 shares Expires 2034-08-11 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on July 29, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document
June 28, 2024 Filed Jul 3, 2024 00:07 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantCommon Stock	1,452	$0.00	$0.00	Disclosure SEC source: 0001415889-24-019057 · form4-07032024_120720.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,904 F1 · shares: These securities are fully vested restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The amount reflects partial payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document
March 29, 2024 Filed Apr 2, 2024 22:25 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantCommon Stock	1,452	$0.00	$0.00	Disclosure SEC source: 0001415889-24-009851 · form4-04022024_100411.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,452 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The amount reflects partial payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document
March 12, 2024 Filed Mar 14, 2024 22:03 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantStock Option (right to buy) · Derivative	29,400	$0.00 Strike: $9.95	$0.00	Disclosure SEC source: 0001415889-24-008035 · form4-03142024_100343.xml · derivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2034-03-12 F1 · derivative.exercise_date: 1/12 of the shares subject to the option shall vest each month following the Issuer's 2024 Annual Meeting of Stockholders on the same day of the month, subject to Reporting Person remaining a Service Provider through each such date. Notwithstanding the foregoing, the shares subject to the option will be fully vested no later than the date of the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerPerformance Restricted Stock Units · Derivative	5,174	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 10 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,174 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8 · price: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11 · derivative.exercise_date: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. F11 · derivative.expiration_date: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerPerformance Restricted Stock Units · Derivative	5,174	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 9 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,174 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8 · price: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11 · derivative.exercise_date: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. F11 · derivative.expiration_date: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerPerformance Restricted Stock Units · Derivative	10,349	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 8 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,349 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8 · price: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F10 · derivative.exercise_date: The Ordinary Shares subject to the PSUs vest on January 5, 2026. F10 · derivative.expiration_date: The Ordinary Shares subject to the PSUs vest on January 5, 2026. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerPerformance Restricted Stock Units · Derivative	21,426	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 7 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,426 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8 · price: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F9 · derivative.exercise_date: The Ordinary Shares subject to the PSUs vest on January 5, 2025. F9 · derivative.expiration_date: The Ordinary Shares subject to the PSUs vest on January 5, 2025. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerPerformance Restricted Stock Units · Derivative	12,854	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 6 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,854 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8 · price: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F9 · derivative.exercise_date: The Ordinary Shares subject to the PSUs vest on January 5, 2025. F9 · derivative.expiration_date: The Ordinary Shares subject to the PSUs vest on January 5, 2025. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerPerformance Restricted Stock Units · Derivative	4,285	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 5 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,285 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8 · price: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F7 · derivative.exercise_date: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4") vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025. F7 · derivative.expiration_date: The Ordinary Shares subject to the PSUs (as defined in footnote 8 to this Form 4") vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerRestricted Stock Units · Derivative	20,697	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 4 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,697 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4 · price: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F6 · derivative.exercise_date: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023. F6 · derivative.expiration_date: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerRestricted Stock Units · Derivative	14,283	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 3 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,283 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4 · price: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F5 · derivative.exercise_date: The Ordinary Shares subject to the RSUs vest ratably on January 5, 2024 and January 5, 2025. F5 · derivative.expiration_date: The Ordinary Shares subject to the RSUs vest ratably on January 5, 2024 and January 5, 2025. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerRestricted Stock Units · Derivative	4,657	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · derivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,657 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU (as defined in footnote 4 to this Form 4) and PSU (as defined in footnote 8 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F4 · price: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 8 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F3 · derivative.exercise_date: The Ordinary Shares subject to the RSUs (as defined in footnote 4 to this Form 4") vest on January 5, 2024. F3 · derivative.expiration_date: The Ordinary Shares subject to the RSUs (as defined in footnote 4 to this Form 4") vest on January 5, 2024. Read SEC document
October 06, 2023 Filed Oct 6, 2023 22:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Disposition to issuerOrdinary Shares	14,575	$116.50	$1,697,987.50	Disclosure SEC source: 0001209191-23-052363 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). Read SEC document
October 03, 2023 Filed Oct 5, 2023 23:43 UTC	IGM Biosciences, Inc. IGMS · Entity 76422	GrantStock Option (right to buy) · Derivative	31,000	$0.00 Strike: $6.71	$0.00	Disclosure SEC source: 0001209191-23-052262 · doc4.xml · derivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2033-10-03 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on October 3, 2024 and 1/36 of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
March 13, 2023 Filed Mar 14, 2023 20:45 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-018502 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,575 Read SEC document
January 04, 2023 Filed Jan 6, 2023 22:43 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units (RSU) · Derivative	20,697	$0.00	$0.00	Disclosure SEC source: 0001209191-23-002435 · doc4.xml · derivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,697 Underlying: Ordinary Shares · 20,697 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSUs vest 1/3rd annually on each anniversary of January 5, 2023. F2 · derivative.expiration_date: The RSUs vest 1/3rd annually on each anniversary of January 5, 2023. Read SEC document
December 30, 2022 Filed Jan 4, 2023 21:18 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	7,141	$0.00	$0.00	Disclosure SEC source: 0001209191-23-000896 · doc4.xml · derivative · entry 5 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,283 Underlying: Ordinary Shares · 7,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025. F4 · derivative.expiration_date: The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025. Read SEC document
December 30, 2022 Filed Jan 4, 2023 21:18 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	4,657	$0.00	$0.00	Disclosure SEC source: 0001209191-23-000896 · doc4.xml · derivative · entry 4 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,657 Underlying: Ordinary Shares · 4,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The remaining ordinary shares subject to the RSU vest on January 5, 2024. F3 · derivative.expiration_date: The remaining ordinary shares subject to the RSU vest on January 5, 2024. Read SEC document
December 30, 2022 Filed Jan 4, 2023 21:18 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	7,257	$0.00	$0.00	Disclosure SEC source: 0001209191-23-000896 · doc4.xml · derivative · entry 3 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The final tranche of ordinary shares subject to the RSU vested on December 30, 2022. F2 · derivative.expiration_date: The final tranche of ordinary shares subject to the RSU vested on December 30, 2022. Read SEC document
December 30, 2022 Filed Jan 4, 2023 21:18 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	9,449	$113.80	$1,075,296.20	Disclosure SEC source: 0001209191-23-000896 · doc4.xml · nonDerivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,575 Read SEC document
December 30, 2022 Filed Jan 4, 2023 21:18 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	19,055	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-000896 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
July 20, 2022 Filed Jul 20, 2022 22:19 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	5,917	$85.00	$502,945.00	Disclosure SEC source: 0001209191-22-042767 · doc4.xml · nonDerivative · entry 3 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,969 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document
July 19, 2022 Filed Jul 20, 2022 22:19 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	82	$85.04	$6,973.28	Disclosure SEC source: 0001209191-22-042767 · doc4.xml · nonDerivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,886 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document
July 19, 2022 Filed Jul 20, 2022 22:19 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	8	$85.02	$680.12	Disclosure SEC source: 0001209191-22-042767 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document
July 07, 2022 Filed Jul 11, 2022 22:03 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	82	$85.01	$6,970.82	Disclosure SEC source: 0001209191-22-041840 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,976 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. Read SEC document
April 18, 2022 Filed Apr 20, 2022 20:13 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	8,098	$115.64	$936,452.72	Disclosure SEC source: 0001209191-22-024924 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,058 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2022. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.96 to $116.185 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 05, 2022 Filed Jan 7, 2022 02:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	4,657	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002295 · doc4.xml · derivative · entry 6 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,314 Underlying: Ordinary Shares · 4,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2021. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2021. Read SEC document
January 05, 2022 Filed Jan 7, 2022 02:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	7,257	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002295 · doc4.xml · derivative · entry 5 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,257 Underlying: Ordinary Shares · 7,257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
January 05, 2022 Filed Jan 7, 2022 02:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	2,085	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002295 · doc4.xml · derivative · entry 4 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,085 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document
January 05, 2022 Filed Jan 7, 2022 02:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	7,030	$101.84	$715,935.20	Disclosure SEC source: 0001209191-22-002295 · doc4.xml · nonDerivative · entry 2 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,156 Read SEC document
January 05, 2022 Filed Jan 7, 2022 02:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	13,999	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-22-002295 · doc4.xml · nonDerivative · entry 1 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 04, 2022 Filed Jan 7, 2022 02:01 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units (RSU) · Derivative	21,424	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002295 · doc4.xml · derivative · entry 3 Thompson Elizabeth H.Z. · CIK 0001861477 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,424 Underlying: Ordinary Shares · 21,424 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. F2 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2022. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.